<DOC>
	<DOCNO>NCT01259375</DOCNO>
	<brief_summary>Primary Objectives 1 . To evaluate Response Rate ( RR ) amrubicin patient metastatic advance sarcoma first line therapy . 2 . To evaluate Progression Free Survival ( PFS ) . Secondary Objectives 1 . To assess safety tolerability amrubicin patient population . 2 . To evaluate whether certain histologic subtypes sarcoma demonstrate differential response amrubicin . 3 . To investigate quality response radiographic evaluation use Response Evaluation Criteria In Solid Tumors ( RECIST ) Choi criterion . 4 . To evaluate overall survival ( OS ) .</brief_summary>
	<brief_title>Amrubicin Chemotherapy First Line Metastatic Unresectable Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<criteria>Adult patient ( age 18 year old ) Pathological diagnosis soft tissue sarcoma . Pathology material must submit reviewed . Patients must unresectable locally advanced metastatic progressive disease prior enrollment . Disease extent must determine scan ( CT PET CT ) within 6 week enrollment . No prior chemotherapy soft tissue sarcoma . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate organ function include follow : Adequate bone marrow reserve : absolute neutrophil count ( segmented band ) ( ANC ) 1.5 x 109/L , platelet count 100 x 109/L , hemoglobin 90 g/L , Hepatic : bilirubin 1.5 x upper limit normal ( ULN ) , ALT AST 3.0 x ULN , Renal : serum creatinine 1.5 x ULN calculate creatinine clearance great 60 mL/min , Cardiac : Left ventricular ejection fraction ( LVEF ) 50 % echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) ; All lab must do within 2 week prior enrollment . Negative serum pregnancy test time enrollment female childbearing potential ; For male female childproducing potential , use effective contraceptive method study ; Ability understand requirement study provide write informed consent . Pregnant nursing female Chest radiotherapy curative intent primary disease complex less equal 28 day prior first dose ; cranial radiotherapy less equal 21 day prior first dose ; radiotherapy area less equal 7 day prior first dose Concurrent severe uncontrolled medical disease ( eg , active systemic infection , diabetes , hypertension , coronary artery disease , congestive heart failure , active viral hepatitis chronic liver disease ) , opinion investigator , would compromise safety patient compromise ability patient complete study Symptomatic central nervous system metastasis . Patients asymptomatic brain metastasis allow . The patient must stable 2 week radiotherapy ; patient corticosteroid , dose corticosteroid must stable 2 week prior first dose study treatment , process taper Suspected , diffuse idiopathic interstitial lung disease pulmonary fibrosis . Patients known history seropositive human immunodeficiency virus ( HIV ) patient receive immunosuppressive medication would , opinion investigator , increase risk serious neutropenic complication . HIV test require inclusion trial . Known hypersensitivity component i.v . formulation amrubicin . Psychiatric disorder personal circumstance prevent compliance study protocol . Inability unwillingness comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>